Roche Primes New Push Via Cipla For Avastin, Actemra In India
Yesteryear rivals Roche and Cipla have sewn up a partnership under which Cipla will market a second brand of the Swiss giant’s Avastin (bevacizumab) and the
You may also be interested in...
A string of actions to ensure medicines security and prioritize bulk drug project clearances are underway in India as the country enters a critical phase in its efforts to contain coronavirus cases.
Roche's India head, Lara Bezerra, seen as unconventional in her overall strategic approach, is heading out of the company. Speculation is rife that questions around "business deliverables" may have contributed to the decision.
Eisai has struck a deal with Mylan for a second brand of Halaven in India, joining a growing list of foreign firms deploying this approach to expand access to novel therapies in the country amid emerging competition.